step semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial STEP-HFpEF Trial

GLP-1 RAs surprised scientists and doctors when it became clear that obese patients prescribed the drug for blood glucose control were losing weight

The potential to lose 1520% of body weight, coupled with improvements in physical health markers like blood sugar control, cardiovascular health, and even reduced food noise, has made these medications a game-changer for many

Research shows that some weight loss from the medication involves muscle loss rather than fat loss

This verification process ensures research reliability by eliminating variability that can affect experimental outcomes or data interpretation

Most gastrointestinal side effects diminish significantly after 48 weeks of continuous treatment at a stable dose, though individual experiences vary considerably